APA (7th ed.) Citation

SB, S., JS, S., M, C., LA, F., GM, T., DD, B., . . . AR, Z. (1998). Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. Gut, 42(5), 628. https://doi.org/10.1136/gut.42.5.628

Chicago Style (17th ed.) Citation

SB, Saslow, Scolapio JS, Camilleri M, Forstrom LA, Thomforde GM, Burton DD, Rubin J, Pitot HC, and Zinsmeister AR. "Medium-term Effects of a New 5HT3 Antagonist, Alosetron, in Patients with Carcinoid Diarrhoea." Gut 42, no. 5 (1998): 628. https://doi.org/10.1136/gut.42.5.628.

MLA (9th ed.) Citation

SB, Saslow, et al. "Medium-term Effects of a New 5HT3 Antagonist, Alosetron, in Patients with Carcinoid Diarrhoea." Gut, vol. 42, no. 5, 1998, p. 628, https://doi.org/10.1136/gut.42.5.628.